AIs and SERMs in Male Infertility: Clinical Indications

Primary Indication: Low Testosterone

AIs and SERMs are indicated for infertile men with low serum testosterone, but their benefits are limited compared to assisted reproductive technology (ART), and they should not be used as first-line therapy for idiopathic infertility, as recommended by The Journal of Urology 1, 2
Clinicians may use aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs), human chorionic gonadotropin (hCG), or combinations thereof specifically for infertile men with documented low serum testosterone, representing a conditional recommendation with Grade C evidence level, according to The Journal of Urology 1, 2, 3, 4

For men with idiopathic infertility, clinicians must inform patients that SERMs have limited benefits relative to ART results, as stated by The Journal of Urology 1, 2, 4

Patients with NOA should be informed of the limited data supporting pharmacologic manipulation with SERMs, AIs, and gonadotropins prior to surgical intervention, representing a conditional recommendation with Grade C evidence level, according to The Journal of Urology 1, 3, 4

Testosterone monotherapy must never be prescribed for males interested in current or future fertility, as it suppresses spermatogenesis through negative feedback on the hypothalamic-pituitary axis, as recommended by The Journal of Urology 1, 2, 3, 4

Men with elevated FSH (>7.6 IU/L) suggesting testicular dysfunction but who still have some spermatogenic potential may benefit from AI/SERM therapy, according to Praxis Medical Insights 5

If low testosterone with abnormal T/E2 ratio, consider AI therapy (anastrozole 1 mg/day or letrozole 2.5 mg/day) or SERM therapy, as recommended by The Journal of Urology 1
Monitor response by repeating semen analysis after at least 2.5 months (74 days) to assess spermatogenic response, according to Praxis Medical Insights 5, 6
If inadequate response or time-sensitive fertility, transition to ART (IVF/ICSI), which provides superior pregnancy outcomes, as stated by The Journal of Urology and Praxis Medical Insights 1, 6

Medical treatments may delay more effective ART options, emphasizing the importance of timely counseling about realistic expectations, according to Praxis Medical Insights 6

The American Urological Association recommends clomiphene citrate dosing at 25 mg orally daily for 25 consecutive days followed by 5 days of rest, with this cycle repeated for at least 3 months to allow sufficient time for spermatogenesis 7

The American Urological Association suggests that clomiphene should only be considered for men with documented low testosterone and infertility, not as first-line therapy for idiopathic infertility with normal testosterone 7
Appropriate candidates for clomiphene include men with low serum testosterone and abnormal semen parameters, with the Endocrine Society recommending this treatment option 7

For men with total motile sperm count <10 million, the European Society of Human Reproduction and Embryology recommends considering clomiphene 25 mg daily if low testosterone is documented, and counseling that IUI in natural cycles is appropriate for this group 7, 8
The American Society for Reproductive Medicine recommends that if no improvement after 3 months or time-sensitive fertility concerns, transition directly to IVF/ICSI 7

The American Urological Association notes that female partner age is the most critical factor determining conception success, and delaying ART for empiric clomiphene trials may reduce overall pregnancy chances 7
For non-obstructive azoospermia (NOA), the European Association of Urology recommends that clomiphene has extremely limited evidence and should not delay surgical sperm retrieval options like microsurgical testicular sperm extraction (micro-TESE) 7

The American Urological Association notes that clomiphene is not FDA-approved for use in men and represents off-label prescribing 9
The benefits of clomiphene are distinctly limited compared to assisted reproductive technology (ART), which offers higher pregnancy rates and shorter time to conception, as reported by The Journal of Urology 9
For men with non-obstructive azoospermia (NOA), clomiphene has extremely limited evidence and should not delay surgical sperm retrieval options like microsurgical testicular sperm extraction (micro-TESE), according to The Journal of Urology 10
Patients with NOA should be informed that data supporting pharmacologic manipulation with SERMs (including clomiphene) prior to surgical intervention is minimal, as stated by The Journal of Urology 10